ELDRED KARY

Average Profitability
15.99%
Insider Buys Quantity
10
Insider Buys Sum
$46,218.65
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of ELDRED KARY

According to the SEC Form 4 filings, ELDRED KARY, being in a position of

  1. director at Galectin Therapeutics Inc.,
    оver the last 12 months, has bought 14369 shares for $13,301, and sold 0 shares,
    over all time since 2018-09-25, has bought 24200 shares for $46,219, and sold 0 shares.

The largest purchase of all time was on 2019-05-31 and amounted to 3033 shares of Galectin Therapeutics Inc. for $12,981.

Biography of ELDRED KARY

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $13,3013100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2024-12-24PurchaseGalectin Therapeutics Inc.
GALT
director
13,469
0.0211%
$0.82$11,045+53.46%
2024-10-23PurchaseGalectin Therapeutics Inc.
GALT
director
500
0.0008%
$2.60$1,300-38.66%
2024-07-22PurchaseGalectin Therapeutics Inc.
GALT
director
400
0.0006%
$2.39$956-6.65%
2024-01-16PurchaseGalectin Therapeutics Inc.
GALT
director
500
0.0008%
$1.79$893+37.36%
2024-01-16PurchaseGalectin Therapeutics Inc.
GALT
director
400
0.0008%
$2.39$956+37.36%
2023-07-19PurchaseGalectin Therapeutics Inc.
GALT
director
1,598
0.0028%
$1.79$2,854+16.37%
2023-02-21PurchaseGalectin Therapeutics Inc.
GALT
1,000
0.0017%
$1.59$1,591+10%
2023-01-25PurchaseGalectin Therapeutics Inc.
GALT
director
1,300
0.0022%
$1.11$1,443+60%
2019-05-31PurchaseGalectin Therapeutics Inc.
GALT
director
3,033
0.0064%
$4.28$12,981-23.33%
2018-09-25PurchaseGalectin Therapeutics Inc.
GALT
director
2,000
0.0049%
$6.10$12,200-25.86%
Total: 10
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.